Jiang Yuan used his genetic technology far beyond this era to customize different gene signature production methods for each OEM manufacturer.
Gene signatures can be written directly into the S rod, and SCV1 will detect the presence of a gene signature that meets the requirements when absorbing the energy of the S rod.
If it is not present or cannot pass the test, the SCV1 cells will refuse to absorb this energy.
Just like the SCV1 cell production technology that other companies and research institutions cannot crack, the technical difficulty of gene signatures is basically the same, which ensures that each manufacturer can only use unique gene signatures to produce S rods.
If there is a pirated S stick on the market, Shensi Group only needs to detect the genetic signature of the pirated S stick to know which manufacturer leaked the gene signature technology.
The DeepThink Group will immediately update the SCV1 testing program and refuse to accept S-rods that use this pirated genetic signature.
S sticks that have been produced but have not yet been sold are no longer allowed to enter the consumer market; S sticks that have been sold to users must be recalled by the manufacturer and bear the loss.
In addition, Shensi Group will also hold the cooperative manufacturers who leaked the genetic signatures accountable in accordance with the provisions of the contract, and sky-high liquidated damages are waiting for them.
The reason why such harsh conditions can be accepted by Pfizer is entirely because of interests.
First of all, the sales of DT3 have far exceeded many people's imagination.
It is predictable that due to the impact of DT3, the sales of a large number of drugs will continue to decline in the next few years.
Pfizer is not immune, with revenue estimated to plummet by around 30 to 40 percent in three years.
The resulting collapse in market value will be more terrible than the decline in revenue, and the executives of pharmaceutical companies will be under tremendous pressure from the board of directors.
Without a solution that can turn things around in a short period of time, many people will lose their positions with lucrative commissions.
The S-stick is their lifesaver!
Even if you don't make much money on it, it will give the stock market a lot of confidence, ensuring that Pfizer's market value will not decrease too much, and if you are lucky, maybe you can increase a little bit to keep everyone's position.
Jiang Yuan knows very well that compared with agreement and persecution, interests are a stronger chain.
Therefore, he left Pfizer with other windows to make money, and he did not squeeze them too much.
While Pfizer doesn't make much money from the base S-stick, they can develop a more advanced version.
For example, they can provide more flavors, or add different nutrients, as long as they can sell them, no matter how high the price is, Shensi Group will not care.
As long as the basic version doesn't increase the price.
For example, Pfizer can produce a fully nutritious version of the S bar, which not only provides the energy needed for SCV1, but also provides nutrients such as vitamins that the body needs every day.
It's not too much to sell this kind of full nutrition version for two or three dollars, right?
According to the agreement, Shengshi Group only takes 20% of the revenue of more than one dollar.
In other words, as long as the sales of the non-basic version are high enough, Pfizer's profit is still very impressive.
In addition to this, Pfizer can also produce a variety of flavors such as chocolate, cocoa, coffee, milk, cherry......
This is completely left to the manufacturers to explore on their own, as long as they can sell it, Shensi Group is happy to see it, anyway, it is a commission.
It can be said that Shensi Group has firmly tied Pfizer to its chariot with the benefits of solving the current stock market crash and the huge profits that can be foreseen in the future.
Unless there is another company that can produce SCV1 cell robots, it is absolutely impossible for Pfizer and other cooperative companies to betray Shensi Group, and they cannot afford the risk and loss of betrayal.
Of course, the dominant Shensi Group will not bind itself only to Pfizer.
In addition to Pfizer, there are seven or eight other companies waiting for Lin Ruqing to negotiate with them.
They will put pressure and competition on Pfizer, and although Eberle is not happy, there is nothing to be done. ......
The number of terrifying reservations in DT3 made the entire Shensi Group busy, and the production resources prepared by Lin Ruqing in the early stage were not enough.
The entire production chain is already tightly taut and still unable to meet the needs.
The current 200 million reservations and estimated sales volume of 500 million have exceeded the maximum production capacity.
If it weren't for the capacity problem, Pfizer would definitely have to pay a greater price if it wanted to get the cooperation contract.
Lin Ruqing naturally wants to increase production capacity as soon as possible, in addition, it is also very important to integrate the production chain.
Jiang Yuan asked Cook about it.
Integrating the production chain, improving production efficiency, reducing costs, and increasing profits are all things that Cook is a master of.
Due to the slow sales of the DT2 and the expected decline in sales of iGlass, Cook is a little more idle at the moment and has time to take over the job 。
Commenting on this work, Cook looked at all the production data and said: "We have to renegotiate with the raw material manufacturers, and it is very possible to reduce the cost by 20%.
With such a high sales volume, Shensi Group has the absolute initiative and bargaining power!
If you don't reduce costs ruthlessly, you are irresponsible for the interests of the group. ” The price of DT3 is 2999 yuan, which is actually a loss, and every DT3 Shensi Group will suffer a loss of about 1,000 yuan.
This is in line with the expectations of the outside world, and there have been many media speculations before that the current behavior of Shensi Group is to make money at a loss, and Jiang Yuan is betting that the sales of DT3 can reach a certain threshold.
As long as the sales volume exceeds a certain value, the second world ecosystem will be established, and the DT3 can also reduce costs and losses.
Free novels bring you joy and joy ---> storyskyline.net
In the future, the main source of profit for Shensi Group will definitely come from the income of consumables S rod and the second world ecosystem.
That being said, who likes to lose money?
If Cook can reduce it by 20%, the current loss of Shensi Group will be very small, and the profit time will be advanced.
Jiang Yuan trusted Cook's ability to control production, so he quietly issued a task to mobilize Cook's enthusiasm, and then completely handed over the work to him.
Cook was also happy to accept the job.
At present, Apple's stock fluctuates up and down like a roller coaster, and Apple's shareholders are not sure what Jiang Yuan will do with Apple.
Although Jiang Yuan has made it clear that he will not consider licensing SCV1 to Apple to develop new products for the time being, shareholders can't believe Jiang Yuan's words.
Because he had done something similar before, first lowering Apple's stock, and then pulling it up by licensing the production of iGlass, making a huge amount of dollars.
But it's also dangerous not to sell stocks, who knows if Jiang Yuan is playing real this time?
Because Shensi Group has been reducing its stake in Apple for half a year, it is possible for Jiang Yuan to withdraw.